Effect of Harmine on Nicotine-Induced Kidney Dysfunction in Male Mice.
Harmine
kidney
nicotine
Journal
International journal of preventive medicine
ISSN: 2008-7802
Titre abrégé: Int J Prev Med
Pays: Iran
ID NLM: 101535380
Informations de publication
Date de publication:
2019
2019
Historique:
received:
22
07
2018
accepted:
13
12
2018
entrez:
31
7
2019
pubmed:
31
7
2019
medline:
31
7
2019
Statut:
epublish
Résumé
The nicotine content of cigarettes plays a key role in the pathogenesis of kidney disease. Harmine is a harmal-derived alkaloid with antioxidant properties. This study was designed to evaluate the effects of harmine against nicotine-induced damage to the kidneys of mice. In this study, 64 male mice were randomly assigned to eight groups: saline and nicotine-treated groups (2.5 mg/kg), harmine groups (5, 10, and 15 mg/kg), and nicotine (2.5 mg/kg) + harmine-treated groups (5, 10, and 15 mg/kg). Treatments were administered intraperitoneally daily for 28 days. The weights of the mice and their kidneys, kidney index, glomeruli characteristics, thiobarbituric acid reactive species, antioxidant capacity, kidney function indicators, and serum nitrite oxide levels were investigated. Nicotine administration significantly improved kidney malondialdehyde (MDA) level, blood urea nitrogen (BUN), creatinine, and nitrite oxide levels and decreased glomeruli number and tissue ferric reducing/antioxidant power (FRAP) level compared to the saline group ( It seems that harmine administration improved kidney injury induced by nicotine in mice.
Sections du résumé
BACKGROUND
BACKGROUND
The nicotine content of cigarettes plays a key role in the pathogenesis of kidney disease. Harmine is a harmal-derived alkaloid with antioxidant properties. This study was designed to evaluate the effects of harmine against nicotine-induced damage to the kidneys of mice.
METHODS
METHODS
In this study, 64 male mice were randomly assigned to eight groups: saline and nicotine-treated groups (2.5 mg/kg), harmine groups (5, 10, and 15 mg/kg), and nicotine (2.5 mg/kg) + harmine-treated groups (5, 10, and 15 mg/kg). Treatments were administered intraperitoneally daily for 28 days. The weights of the mice and their kidneys, kidney index, glomeruli characteristics, thiobarbituric acid reactive species, antioxidant capacity, kidney function indicators, and serum nitrite oxide levels were investigated.
RESULTS
RESULTS
Nicotine administration significantly improved kidney malondialdehyde (MDA) level, blood urea nitrogen (BUN), creatinine, and nitrite oxide levels and decreased glomeruli number and tissue ferric reducing/antioxidant power (FRAP) level compared to the saline group (
CONCLUSIONS
CONCLUSIONS
It seems that harmine administration improved kidney injury induced by nicotine in mice.
Identifiants
pubmed: 31360344
doi: 10.4103/ijpvm.IJPVM_85_18
pii: IJPVM-10-97
pmc: PMC6592107
doi:
Types de publication
Journal Article
Langues
eng
Pagination
97Déclaration de conflit d'intérêts
There are no conflicts of interest.
Références
Arch Environ Contam Toxicol. 1999 Nov;37(4):434-9
pubmed: 10508890
Hepatology. 2002 Dec;36(6):1349-54
pubmed: 12447858
Biochem Biophys Res Commun. 2005 Dec 23;338(3):1557-63
pubmed: 16288723
J Pharmacol Exp Ther. 2007 Feb;320(2):837-44
pubmed: 17093131
Nat Rev Neurosci. 2007 Oct;8(10):766-75
pubmed: 17882254
Biochem Pharmacol. 1991 Jul 15;42(3):459-64
pubmed: 1859459
J Environ Biol. 2008 Jan;29(1):73-7
pubmed: 18831335
Brain Res Bull. 2010 Mar 16;81(4-5):491-6
pubmed: 19772900
Oxid Med Cell Longev. 2010 Sep-Oct;3(5):325-31
pubmed: 21150338
Chem Pharm Bull (Tokyo). 2011;59(3):388-91
pubmed: 21372424
Molecules. 2013 Jan 04;18(1):666-81
pubmed: 23292329
Biochem Pharmacol. 2013 Oct 15;86(8):1215-23
pubmed: 23892062
Pak J Biol Sci. 2013 Dec 1;16(23):1687-97
pubmed: 24506035
Int J Prev Med. 2015 Sep 10;6:92
pubmed: 26442615
Nicotine Tob Res. 2016 Jul;18(7):1628-34
pubmed: 26896163
J Tradit Complement Med. 2015 Jan 31;6(2):176-83
pubmed: 27114942
Exp Physiol. 2016 Jul 1;101(7):913-31
pubmed: 27121856
Int J Reprod Biomed (Yazd). 2016 Feb;14(2):95-102
pubmed: 27200423
Pak J Pharm Sci. 2016 Jul;29(4):1317-20
pubmed: 27393444
Asian Pac J Cancer Prev. ;18(1):239-244
pubmed: 28240526
Iran J Kidney Dis. 2017 Mar;11(2):142-150
pubmed: 28270647
Phytomedicine. 2017 May 15;28:10-18
pubmed: 28478808
Brain Res Bull. 2018 Mar;137:294-300
pubmed: 29330035
Naunyn Schmiedebergs Arch Pharmacol. 1974;285(3):273-92
pubmed: 4282118
FEBS Lett. 1995 Jul 17;368(2):225-9
pubmed: 7628610
Life Sci. 1996;58(17):1425-32
pubmed: 8622568